Kronos Bio (KRON) Revenue & Revenue Breakdown
Kronos Bio Revenue Highlights
Latest Revenue (Y)
$6.29M
Latest Revenue (Q)
$2.69M
Kronos Bio Revenue by Period
Kronos Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.29M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Kronos Bio generated $6.29M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kronos Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.69M | 6.67% |
| 2024-03-31 | $2.52M | 10.24% |
| 2023-12-31 | $2.29M | 149.29% |
| 2023-09-30 | $917.00K | -50.80% |
| 2023-06-30 | $1.86M | 52.66% |
| 2023-03-31 | $1.22M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Kronos Bio generated $2.69M in revenue during Q2 2024, up 6.67% compared to the previous quarter, and up 220.15% compared to the same period a year ago.
Kronos Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| MRUS | Merus | $43.95M | $7.33M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| INBX | Inhibrx | $1.80M | - |
| ADXN | Addex Therapeutics | $1.61M | $235.00K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| CCCC | C4 Therapeutics | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| NXTC | NextCure | - | - |
| REPL | Replimune Group | - | - |
| ERAS | Erasca | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| CYCN | Cyclerion Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
KRON Revenue FAQ
What is Kronos Bio’s yearly revenue?
Kronos Bio's yearly revenue for 2023 was $6.29M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. KRON's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Kronos Bio’s quarterly revenue?
Kronos Bio's quarterly revenue for Q2 2024 was $2.69M, a 6.67% increase from the previous quarter (Q1 2024), and a 44.21% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.52M, a 10.24% increase from the previous quarter (Q4 2023), and a 106.39% increase year-over-year (Q1 2023). KRON's quarterly revenue for Q4 2023 was $2.29M, a 149.29% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Kronos Bio’s revenue growth rate?
Kronos Bio's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.